---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-045445"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:14:47.087531+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports positive PRO data from Phase 3 VERITAC-2 for vepdegestrant in ESR1-mutated breast cancer

## Summary
- Vepdegestrant showed reduced risk of deterioration vs fulvestrant in overall health status, pain severity, and functioning domains; statistically significant.
- PRO data presented at ESMO 2025 support vepdegestrant as potential best-in-class therapy for ESR1-mutated ER+/HER2- metastatic breast cancer.
- Also presented TACTIVE-N Phase 2 results: neoadjuvant vepdegestrant demonstrated biological and clinical activity in localized breast cancer.
- Vepdegestrant is a PROTAC ER degrader developed with Pfizer; previously reported statistically significant PFS improvement.

## SEC filing metadata
- accession: 0001628280-25-045445
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/0001628280-25-045445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/arvn-20251020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-045445
- JSON: https://secwatch.observer/filing/0001628280-25-045445.json
- Plain text: https://secwatch.observer/filing/0001628280-25-045445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.